Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 110

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 110
---
 Iroquois Master Fund. The principal business address of Iroquois Master Fund Ltd. is c/o Iroquois Capital Management,          
 LLC, 2 Overhill Road, Suite 400, Scarsdale, NY 10583.                                                                                         |

| (8) | The selling                                                                                                                                   
 shareholder holds (i) warrants issued by us in prior transactions which entitle the selling shareholder                                       
 to purchase an aggregate of 309,660,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Series                                   
 J Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary Shares (in the form of         
 Depositary Shares) and Series K Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 425,530,000 Ordinary  
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 4.99%, which does not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts      
 and percentages in the table do not give effect to the 4.99% beneficial ownership limitation, if applicable. The principal business address   
 of Ionic Ventures, LLC is 3053 Fillmore Street, Suite 2565, San Francisco, CA 94123.                                                          |

| (9) | The selling                                                                                                                                    
 shareholder (i) warrants issued by us in prior transactions which entitle the selling shareholder                                              
 to purchase an aggregate of 316,310,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Series                                    
 J Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 4,250,000 Ordinary Shares (in the form of Depositary 
 Shares) and Series K Warrants issued by us which entitle the selling shareholder to purchase an aggregate of 4,250,000 Ordinary Shares         
 (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation          
 of 4.99%, which does not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder  
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts       
 and percentages